These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2427 related articles for article (PubMed ID: 32063474)
1. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474 [TBL] [Abstract][Full Text] [Related]
2. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review. Du J; Zhang Y J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815 [TBL] [Abstract][Full Text] [Related]
3. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048 [TBL] [Abstract][Full Text] [Related]
4. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088 [TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y Front Immunol; 2020; 11():564099. PubMed ID: 33329526 [TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493 [TBL] [Abstract][Full Text] [Related]
7. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260 [TBL] [Abstract][Full Text] [Related]
8. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647 [TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Strati P; Neelapu SS Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158 [TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Hunter BD; Rogalski M; Jacobson CA Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma. Xu H; Lv Q; Huang L; Cao W; Wang J; Meng F; Li C; Zheng M; Chen L; Mu K; Cheng J; Zhu L; Zhou J; Zhang Y; Wang N; Cao Y Cytotherapy; 2023 Feb; 25(2):185-191. PubMed ID: 36283943 [No Abstract] [Full Text] [Related]
12. Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma. Huang L; Li J; Yang J; Zhang X; Zhang M; He J; Zhang G; Li W; Wang H; Li J; Lu P Cells; 2022 Dec; 11(24):. PubMed ID: 36552849 [TBL] [Abstract][Full Text] [Related]
13. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy. Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811 [TBL] [Abstract][Full Text] [Related]
16. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Spiegel JY; Patel S; Muffly L; Hossain NM; Oak J; Baird JH; Frank MJ; Shiraz P; Sahaf B; Craig J; Iglesias M; Younes S; Natkunam Y; Ozawa MG; Yang E; Tamaresis J; Chinnasamy H; Ehlinger Z; Reynolds W; Lynn R; Rotiroti MC; Gkitsas N; Arai S; Johnston L; Lowsky R; Majzner RG; Meyer E; Negrin RS; Rezvani AR; Sidana S; Shizuru J; Weng WK; Mullins C; Jacob A; Kirsch I; Bazzano M; Zhou J; Mackay S; Bornheimer SJ; Schultz L; Ramakrishna S; Davis KL; Kong KA; Shah NN; Qin H; Fry T; Feldman S; Mackall CL; Miklos DB Nat Med; 2021 Aug; 27(8):1419-1431. PubMed ID: 34312556 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma]. Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437 [No Abstract] [Full Text] [Related]
19. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422 [TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. Abramson JS; Lunning M; Palomba ML Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]